TRENDING
XPeng (NYSE: XPEV) Reports Revenue Growth of 19.3% During Third Quarter 2022, But Q4 Outlook Warns of Sharp Decrease in Deliveries
November 30, 2022
Analysts Reiterate Bullish Stance on Asure Software (NASDAQ: ASUR), Collectively Raise Target Price to Average of $11.00
November 30, 2022
Apollo Endosurgery (NASDAQ: APEN) Enters Into Agreement to be Acquired by Boston Scientific (NYSE: BSX) for $615 Million
November 29, 2022
Next
Prev
Newsletter
Opinion
Market Snapshot
Taboola (NASDAQ: TBLA) Signs 30-Year Advertising Collaboration Agreement with Yahoo
Taboola, Inc. (NASDAQ: TBLA) is engaged as an AI-based algorithmic engine platform that partners websites and advertising partners with recommending...
Read morePalisade Bio (NASDAQ: PALI) Awarded Fast Track Designation from U.S. FDA for LB1148
Palisade Bio, Inc. (NASDAQ: PALI) is engaged as a biopharmaceutical company, which is focused on the research and development of...
Read moreImago BioSciences (NASDAQ: IMGO) to be Acquired by Merck (NYSE: MRK) for $1.35 Billion
Imago BioSciences, Inc. (NASDAQ: IMGO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development...
Read moreCytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer
CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company, which is focused on developing innovative treatments for a wide-range...
Read moreInMed Pharmaceuticals (NASDAQ: INM) Says Research Grant to Test Cannabinoid Analogs as a Potential Treatment for Alzheimer’s, Parkinson’s and Huntington’s Disease
InMed Pharmaceuticals, Inc. (NASDAQ: INM) is a pharmaceutical research and development company that is focused on utilizing cannabinoids and related...
Read moreLatest News
Palisade Bio (NASDAQ: PALI) Awarded Fast Track Designation from U.S. FDA for LB1148
Palisade Bio, Inc. (NASDAQ: PALI) is engaged as a biopharmaceutical company, which is focused on the research and development of...
Imago BioSciences (NASDAQ: IMGO) to be Acquired by Merck (NYSE: MRK) for $1.35 Billion
Imago BioSciences, Inc. (NASDAQ: IMGO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development...
